Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | NextCure, Inc.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT03311334 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors |
| terminated |
| Phase 1 / Phase 2 |
| 47 |
| Sumitomo Pharma America, Inc.INDUSTRY |
| 2 |
| Apr 18, 2024 |
| clinicaltrials |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | terminated | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | Fox Chase Cancer CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 16 | THERAPIM PTY LTDINDUSTRY | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04999605 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 8 | AkesoINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT02432690 | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | terminated | Phase 2 | 13 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | terminated | Phase 2 | 26 | University of MiamiOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04891185 | Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer(VIPIDO) | terminated | Phase 2 | 14 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT01133756 | E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 | terminated | Phase 1 / Phase 2 | 7 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | terminated | Phase 2 | 1 | pharmaand GmbHINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 9 | University of Wisconsin, MadisonOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | terminated | Phase 2 | 120 | Marker Therapeutics, Inc.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | terminated | Phase 2 | 6 | Craig L Slingluff, JrOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03955471 | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer(MOONSTONE) | terminated | Phase 2 | 41 | Tesaro, Inc.INDUSTRY | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02499952 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | terminated | Phase 2 | 12 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 2 | 34 | Translational Research in OncologyOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03029611 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | terminated | Phase 2 | 3 | MorphotekINDUSTRY | 2 | Dec 8, 2021 | clinicaltrials |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | terminated | Phase 2 | 5 | ExcellaBio LLCINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | terminated | Phase 1 / Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | terminated | Phase 2 | 21 | University of OklahomaOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer(PAZOFOS) | terminated | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | terminated | Phase 2 | 10 | NanOlogy, LLCINDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03146663 | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 2 | 53 | NuCana plcOTHER | 2 | Feb 21, 2021 | clinicaltrials |
| NCT03622931 | Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines(TRACEII) | terminated | Phase 2 | 21 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT01511055 | Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand | terminated | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT01690468 | PTX-200 and Carboplatin in Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 12 | South Plains Oncology ConsortiumNETWORK | 1 | Aug 27, 2020 | clinicaltrials |
| NCT02326844 | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03587129 | Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | terminated | Phase 2 | 1 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01847677 | Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin(NOVA) | terminated | Phase 2 | 71 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Apr 1, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jul 25, 2024source: clinicaltrials